Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16642)	2/18/2004 2:04:47 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

I have no idea of what the implications of the Citigroup holdings are, except that I consider it to be an obvious positive.

To: Bluegreen who wrote (16642)	2/20/2004 9:51:29 PM
From: Robert K.	Respond to of 17367

Again, I dont know which drug this is. Note the weight..... >Summary: Psoriasis- Moderate to Severe Chronic Plaque (03A-02-93-02) Dr. Bruce Strober is conducting a research study at the NYU School of Medicine for people who weigh between 220 and 330 pounds and have been diagnosed with chronic plaque psoriasis. You may be eligible to participate in this study if you: Are 18 years of age or older Are diagnosed with Chronic Plaque Psoriasis Weigh between 220 and 330 pounds You are not eligible to participate if you are: Currently pregnant or breastfeeding HIV+ Have had a systemic infection (pneumonia, tuberculosis) within the last 3 months